Regeneron (REGN) Received $356.0 Target From Canaccord Genuity; Lattice Semiconductor Has 1 Sentiment

February 21, 2018 - By Richard Conner

Among 33 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), 14 have Buy rating, 1 Sell and 18 Hold. Therefore 42% are positive. Regeneron Pharmaceuticals Inc. has $700 highest and $300 lowest target. $490.12’s average target is 53.96% above currents $318.35 stock price. Regeneron Pharmaceuticals Inc. had 117 analyst reports since July 28, 2015 according to SRatingsIntel. Cowen & Co maintained Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) rating on Wednesday, June 21. Cowen & Co has “Hold” rating and $47500 target. The rating was maintained by Oppenheimer on Thursday, August 3 with “Hold”. The rating was maintained by BMO Capital Markets on Tuesday, July 18 with “Hold”. The stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) earned “Hold” rating by Canaccord Genuity on Wednesday, January 27. BTIG Research upgraded Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) rating on Friday, December 16. BTIG Research has “Buy” rating and $460 target. The firm has “Equal-Weight” rating by Morgan Stanley given on Thursday, November 9. Credit Suisse upgraded the shares of REGN in report on Tuesday, December 20 to “Outperform” rating. The stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has “Market Perform” rating given on Wednesday, July 22 by Northland Capital. The stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) earned “Buy” rating by Argus Research on Thursday, August 6. Citigroup downgraded the stock to “Neutral” rating in Friday, December 1 report.

Lattice Semiconductor Corporation, together with its subsidiaries, develops and sells semiconductor devices in Asia, Europe, and the Americas. The company has market cap of $687.77 million. The firm offers programmable logic devices that consist of five product family lines, such as the ECP, MachXO, iCE40, CrossLink, and programmable mixed signal devices. It currently has negative earnings. It also provides video connectivity application specific standard products, including port processors, port controllers, video processors, transmitters, receivers, bridges, and converters for use in mobile phones, HD TVs, home theater systems, HDMI cable extenders, automotive infotainment, PCs, accessories, projectors, and monitors.




Analysts await Lattice Semiconductor Corporation (NASDAQ:LSCC) to report earnings on May, 8. They expect $0.03 earnings per share, 0.00% or $0.00 from last year’s $0.03 per share. LSCC’s profit will be $3.70 million for 46.46 P/E if the $0.03 EPS becomes a reality. After $-0.02 actual earnings per share reported by Lattice Semiconductor Corporation for the previous quarter, Wall Street now forecasts -250.00% EPS growth.

The stock increased 0.09% or $0.005 during the last trading session, reaching $5.575. About 240,810 shares traded. Lattice Semiconductor Corporation (LSCC) has risen 35.73% since February 21, 2017 and is uptrending. It has outperformed by 19.03% the S&P500.

Tieton Capital Management Llc holds 0.97% of its portfolio in Lattice Semiconductor Corporation for 216,290 shares. Nwq Investment Management Company Llc owns 10.04 million shares or 0.64% of their US portfolio. Moreover, Alpine Associates Management Inc. has 0.53% invested in the company for 3.02 million shares. The Maryland-based Hussman Strategic Advisors Inc. has invested 0.5% in the stock. Alpine Global Management Llc, a New York-based fund reported 250,707 shares.

The stock decreased 1.45% or $4.69 during the last trading session, reaching $318.35. About 356,914 shares traded. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has risen 17.40% since February 21, 2017 and is uptrending. It has outperformed by 0.70% the S&P500.

Analysts await Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to report earnings on May, 3. They expect $5.08 earnings per share, up 135.19% or $2.92 from last year’s $2.16 per share. REGN’s profit will be $546.58 million for 15.67 P/E if the $5.08 EPS becomes a reality. After $4.46 actual earnings per share reported by Regeneron Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 13.90% EPS growth.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, makes, and commercializes medicines for the treatment of serious medical conditions worldwide. The company has market cap of $34.25 billion. The Company’s products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and childrenÂ’s. It has a 30.79 P/E ratio. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer.

Since August 22, 2017, it had 0 insider buys, and 5 selling transactions for $2.48 million activity. BAKER CHARLES A sold 2,000 shares worth $900,000. Another trade for 427 shares valued at $210,693 was made by Landry Robert E on Wednesday, August 30. BROWN MICHAEL S also sold $712,500 worth of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares. Sanofi also bought $80.03M worth of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Wednesday, August 23. The insider GOLDSTEIN JOSEPH L sold $325,600.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: